Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

The Chromebooks that Leon County students have been toting from school to home and back again will have to stay at school for some middle schoolers.

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

Nominees this week included students from Adams High and NorthWood High. Check back on Monday for next week's nominees!

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading ...

As the American School of Hong Kong (ASHK) celebrates its first decade, it reflects on its success in achieving: creating a ...

China NMPA approves Antengene’ IND application for phase Ib/II study of ATG-022 in combo with Keytruda± chemotherapy: Shanghai Wednesday, December 3, 2025, 18:00 Hrs [IST] Ante ...

R ondo Therapeutics has initiated dosing in its Phase I/Ib clinical trial of first-in-class bispecific antibody, RNDO-564, ...

Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...

ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...